Industry News, Suppliers News

Evonik Exceeds Expectations in First Quarter of 2024

Adjusted EBITDA rises 28% to €522 million, while sales volumes are above the prior year for first time in two years.

Author Image

By: DAVID SAVASTANO

Editor, Ink World Magazine

The start into 2024 was better than expected for Evonik. Based on preliminary and unaudited figures, Evonik achieved an adjusted EBITDA of €522 million in the first quarter of 2024 (Q1 2023: €409 million), well above market expectations (Vara Research analyst consensus as of March 26, 2024: €450 million). Adjusted EBITDA increased by 28% compared to the previous year’s quarter. The Specialty Additives and Nutrition & Care divisions recorded the strongest growth. The upturn was dr...

Continue reading this story and get 24/7 access to Ink World magazine for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Ink World magazine Newsletters